{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:03:25Z","timestamp":1791198205990,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,9,17]],"date-time":"2004-09-17T00:00:00Z","timestamp":1095379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent in vitro studies, clinical trials and epidemiological studies have suggested possible interactions between aspirin and other cyclo\u2010oxygenase (COX) inhibitors, such as ibuprofen of the COX\u20102 inhibitors celecoxib and rofecoxib. The objective of this study was to test the effects of aspirin (1, 2.5 and 5\u2003mg\/kg), and ibuprofen (4 and 15\u2003mg\/kg), diclofenac (2.5\u2003mg\/kg), flurbiprofen (2\u2003mg\/kg), celecoxib (7.5\u2003mg\/kg), and rofecoxib (1\u2003mg\/kg), alone or combined on a rat model of arterial thrombosis. Drugs were given orally daily for 7\u2003days, before insertion of an arterio\u2010venous shunt thrombosis system, left in place for 15\u2003min. Main parameter was thrombus weight. Five to 12 rats were used per experiment, and 35 controls overall. Aspirin inhibited thrombus formation in a dose\u2010dependent manner. All NSAIDS given alone also inhibited thrombus formation to approximately the same level as aspirin 1\u2003mg\/kg\/day. Ibuprofen, celecoxib and rofecoxib inhibited the effects of aspirin, but not diclofenac or flurbiprofen. The interactions with aspirin do not seem to affect all NSAIDs to equal levels. The clinical impact of this needs to be confirmed in adequately powered clinical trials or pharmaco\u2010epidemiological studies.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2004.00285.x","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T17:11:34Z","timestamp":1097687494000},"page":"559-563","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Interactions between aspirin and COX\u20102 inhibitors or NSAIDs in a rat thrombosis model"],"prefix":"10.1111","volume":"18","author":[{"given":"Anwar","family":"Umar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdiryim","family":"Yusup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halmurat","family":"Upur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,9,17]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.8.954"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00659-3"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00398-3"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003199"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.3.4.383"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12509-3"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7427.1322"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00343-8"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2003.09.016"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1982.tb09265.x"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17126.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-0038-1648133","article-title":"The characterisation of thrombus development in an improved model of arterio\u2010venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost","volume":"65","author":"Peters R.F.","year":"1991","journal-title":"Thromb. Haemost."},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00091-6"},{"key":"e_1_2_10_17_2","first-page":"558","article-title":"Etoricoxib (MK\u20100663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase\u20102","volume":"296","author":"Riendeau D.","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(89)90210-7"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00339-6"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200202000-00013"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00942-0"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(01)00353-X"},{"key":"e_1_2_10_23_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1055\/s-0037-1615615","article-title":"Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5\u2010HT1B\/5\u2010HT2A receptor antagonist","volume":"85","author":"Berry C.N.","year":"2001","journal-title":"Thromb. Haemost."},{"key":"e_1_2_10_24_2","first-page":"34","article-title":"Administration of a potent antagonist of protease\u2010activated receptor\u20101 (PAR\u20101) attenuates vascular restenosis following balloon angioplasty in rats","volume":"298","author":"Andrade\u2010Gordon P.","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_10_25_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0037-1614009","article-title":"Activity of a sub\u2010cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis","volume":"84","author":"Berry C.N.","year":"2000","journal-title":"Thromb. Haemost."},{"key":"e_1_2_10_26_2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1055\/s-0037-1614577","article-title":"DX\u20109065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model","volume":"81","author":"Tanabe K.","year":"1999","journal-title":"Thromb. Haemost."},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701566"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(96)00112-0"},{"key":"e_1_2_10_29_2","first-page":"157","article-title":"Correlation between bleeding time and antithrombotic effect of platelet\u2010suppressive agents in rat experimental model","volume":"83","author":"Suehiro A.","year":"1994","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(01)00344-9"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00201.x"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03966.x"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000087593.07533.9B"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07370-1"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200007000-00004"},{"issue":"25","key":"e_1_2_10_36_2","first-page":"S41","article-title":"The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data","volume":"19","author":"Garcia Rodriguez L.A.","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1111"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02265-2"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.4.481"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02201-9"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2004.00285.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2004.00285.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:00:56Z","timestamp":1697061656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2004.00285.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,17]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1472-8206.2004.00285.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2004.00285.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,17]]},"assertion":[{"value":"2004-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}